Production (Stage)
ReShape Lifesciences Inc.
RSLS
$2.83
$0.155.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.92% | -7.74% | -16.55% | -23.00% | -24.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.92% | -7.74% | -16.55% | -23.00% | -24.82% |
| Cost of Revenue | -8.57% | -5.78% | -42.16% | -39.56% | -33.49% |
| Gross Profit | -16.69% | -8.85% | 5.16% | -11.28% | -19.37% |
| SG&A Expenses | -36.03% | -44.49% | -45.96% | -47.33% | -47.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.10% | -37.07% | -42.04% | -42.67% | -41.95% |
| Operating Income | 43.87% | 54.45% | 55.94% | 53.09% | 50.36% |
| Income Before Tax | 68.43% | 37.45% | 73.27% | 74.56% | 73.60% |
| Income Tax Expenses | -36.54% | -23.08% | 288.57% | 115.71% | 113.13% |
| Earnings from Continuing Operations | 68.28% | 37.38% | 72.98% | 74.09% | 73.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.28% | 37.38% | 72.98% | 74.09% | 73.21% |
| EBIT | 43.87% | 54.45% | 55.94% | 53.09% | 50.36% |
| EBITDA | 43.48% | 54.12% | 54.39% | 50.54% | 46.98% |
| EPS Basic | 28.17% | -129.15% | -- | -- | -- |
| Normalized Basic EPS | 19.59% | -146.92% | -- | -- | -- |
| EPS Diluted | 28.17% | -129.15% | -- | -- | -- |
| Normalized Diluted EPS | 19.59% | -146.92% | -- | -- | -- |
| Average Basic Shares Outstanding | 437.31% | 678.30% | -- | -- | -- |
| Average Diluted Shares Outstanding | 437.31% | 678.30% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |